First-Hand Account: Chemotherapy and Immunotherapy Infusion Begins at Queen's Cancer Center
核心洞察
A patient at Queen's Medical Center (搜索) in Honolulu began a combined chemotherapy and immunotherapy regimen on June 29, 2026, with a five-hour infusion session.
The treatment protocol administers durvalumab, an immunotherapy drug, first, followed sequentially by chemotherapy agents, accompanied by saline and potassium support fluids.
A newly installed chest port was accessed without lidocaine, with the nurse noting the numbing agent "stings more" than the port access needle itself.
A patient undergoing cancer treatment at the Queen's Cancer Center in Honolulu has begun a combined chemotherapy and immunotherapy regimen, providing a detailed first-hand account of the infusion process that offers insight into the patient experience at a major medical center.
The first infusion session took place on Monday, June 29, 2026, in room 412 of the Queen's Cancer Center, located on the fourth floor of the Kuakini Medical Plaza adjacent to Kuakini Hospital. The patient checked in at room 402 before being directed to the infusion area, which features six large reclining chairs with privacy curtains.
Port Access and Preparation
Just days prior to the first infusion, on Thursday, a chest IV port was surgically installed on the patient's right side, below the collarbone. Nurse Pattie, who administered the treatment, noted a shift in clinical practice regarding port utilization. "They used to wait two weeks after the port was put in before moving to treatment," she said. "Probably good for you, but not for us. We're ready to go!" The port was accessed immediately, with the nurse using a length of thin plastic tubing and a special needle attachment from a sterile bag.
Addressing concerns about port access discomfort, Nurse Pattie offered a counterintuitive perspective when the patient mentioned advice about using lidocaine. "Lidocaine stings more than this," she said, instructing the patient to take a deep breath before pressing the needle into place. The patient reported no pain and no sting from the procedure.
Infusion Protocol and Drug Sequencing
The treatment session, estimated at over five hours, followed a structured sequence. Two anti-nausea medications were administered first: a fast-acting agent followed by a long-lasting formulation expected to provide coverage for "a couple of days," according to the nursing staff.
Immunotherapy was administered before chemotherapy, a protocol the nurse described as standard practice. "Immunotherapy is always the first, in all the regimens," Nurse Pattie explained. The immunotherapy agent, durvalumab, began infusing at approximately 9:35 a.m.
The three primary therapeutic drugs were given sequentially rather than as a combined cocktail. All drugs were accompanied by a constant drip of saline solutions, with additional fluids administered after the main agents to flush excess chemicals from the patient's system. A potassium infusion, lasting approximately one hour, was also included to counteract drug-induced depletion of the electrolyte.
Patient Experience
The patient noted the onset of cold sensation approximately one hour into the session, prompting consideration of bringing additional warm clothing to future appointments. The infusion area included a wall-mounted television and a nearby restroom, which the patient noted would be convenient given the duration of treatment.
The session was reported as 10% complete at 9:20 a.m., with the full treatment expected to span more than five hours. The patient was scheduled to continue the regimen with subsequent weekly sessions.